I. B. Kumukova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
I. B. Kumukova has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Evgenevich Trakhtman
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
15 shared publications - Elena E. Kurnikova
Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology Moscow Russia
7 shared publications - Nikolay N. Starostin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
7 shared publications - Dmitriy N. Balashov
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
5 shared publications - E. A. Mamedov
Pirogov Russian National Research Medical University
3 shared publications - Juliya Garloeva
Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology Moscow Russia
3 shared publications
Latest Publications
- 24 April 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 16-21
Packed red blood cell transfusions in perioperative period in patients with gastrointestinal malignancies
Objective. To compare the incidence of postoperative complications in patients with gastrointestinal cancer and anemia depending on red blood cell transfusion. Material and methods. We analyzed treatment outcomes in patients with anemia who underwent surgery between 01.01.2022 and 30.01.2024. The main group included 105 patients who received red blood cell transfusions, the control group — 124 patients without transfusions. We assessed postoperative complications according to the Clavien-Dindo classification, length of hospital stay, readmission, 30-day and 90-day mortality. Results. The study included 229 patients. Transfusions were performed in 105 (45.9%) patients, and there were no transfusions in 124 (54.1%) patients. Postoperative complications were more common in patients with transfusions (26.6% vs. 45.7%, p=0.003) (mainly Clavien-Dindo grade II (15.3% vs. 36.2%, p<0.001) and grade V (0% vs. 7.6%, p=0.002)). In patients with transfusions, hospital stay was 14 days, without transfusion — 11 days (p=0.001). Readmission rate (0% versus 14.3%, p<0.001), 30-day (0% and 6.7%, p=0.004) and 90-day mortality (0% and 11.4%, p<0.001) were higher in the transfusion group. Conclusion. Correction of anemia with red blood cell transfusions in patients with gastrointestinal cancer increases the incidence of postoperative complications, length of hospital stay, readmission rate, 30-day and 90-day mortality.
- 24 April 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 16-21
Packed red blood cell transfusions in perioperative period in patients with gastrointestinal malignancies
Objective. To compare the incidence of postoperative complications in patients with gastrointestinal cancer and anemia depending on red blood cell transfusion. Material and methods. We analyzed treatment outcomes in patients with anemia who underwent surgery between 01.01.2022 and 30.01.2024. The main group included 105 patients who received red blood cell transfusions, the control group — 124 patients without transfusions. We assessed postoperative complications according to the Clavien-Dindo classification, length of hospital stay, readmission, 30-day and 90-day mortality. Results. The study included 229 patients. Transfusions were performed in 105 (45.9%) patients, and there were no transfusions in 124 (54.1%) patients. Postoperative complications were more common in patients with transfusions (26.6% vs. 45.7%, p=0.003) (mainly Clavien-Dindo grade II (15.3% vs. 36.2%, p<0.001) and grade V (0% vs. 7.6%, p=0.002)). In patients with transfusions, hospital stay was 14 days, without transfusion — 11 days (p=0.001). Readmission rate (0% versus 14.3%, p<0.001), 30-day (0% and 6.7%, p=0.004) and 90-day mortality (0% and 11.4%, p<0.001) were higher in the transfusion group. Conclusion. Correction of anemia with red blood cell transfusions in patients with gastrointestinal cancer increases the incidence of postoperative complications, length of hospital stay, readmission rate, 30-day and 90-day mortality.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 14-21
Assessment of transfusion requirements of allogeneic haematopoietic stem cell transplantation recipients and factors influencing it
Introduction. Allogeneic haematopoietic stem cell transplantation (HSCT) is actively used in clinical practice for the treatment of various diseases. Recipients of allogeneic HSCT require significant amounts of transfusion therapy, but the real need for transfusions and factors influencing this need have not been assessed in domestic practice. Materials and methods . A retrospective analysis of the need for transfusions of blood components of recipients of the first allogeneic HSCT performed in 2018–2022 during the observation period of 1 year was performed. The volumes of transfusions performed were calculated for each type of blood components. The transfusion-dependent period is represented by the number of days until the transfusion independence criteria were reached. The incidence of loss of transfusion independence is presented. The influence of various factors on transfusion requirement and transfusion independence was assessed. Results and discussion . The median number of red blood cells transfusions was 2 (IQR 1–4), the median number of platelet transfusions was 5 (IQR 3–10). The only factor that influenced the volume of transfusion therapy was the type of diagnosis more transfusions were required for nonmalignant diseases. The duration of the transfusion-dependent period was influenced by the type of diagnosis, haematopoietic stem cell source and donor type. Gender differences between donor and recipient, as well as differences in ABO and conditioning regime did not influence either transfusion requirement or independence from transfusions. Conclusion. This analysis presents the need for transfusions of donor blood components in allogeneic HSCT recipients during 1 year. The results of the analysis can be used for planning the activities of transplantation centres and blood service institutions to provide transfusion support for HSCT recipients.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 14-21
Open AccessAssessment of transfusion requirements of allogeneic haematopoietic stem cell transplantation recipients and factors influencing it
Introduction. Allogeneic haematopoietic stem cell transplantation (HSCT) is actively used in clinical practice for the treatment of various diseases. Recipients of allogeneic HSCT require significant amounts of transfusion therapy, but the real need for transfusions and factors influencing this need have not been assessed in domestic practice. Materials and methods . A retrospective analysis of the need for transfusions of blood components of recipients of the first allogeneic HSCT performed in 2018–2022 during the observation period of 1 year was performed. The volumes of transfusions performed were calculated for each type of blood components. The transfusion-dependent period is represented by the number of days until the transfusion independence criteria were reached. The incidence of loss of transfusion independence is presented. The influence of various factors on transfusion requirement and transfusion independence was assessed. Results and discussion . The median number of red blood cells transfusions was 2 (IQR 1–4), the median number of platelet transfusions was 5 (IQR 3–10). The only factor that influenced the volume of transfusion therapy was the type of diagnosis more transfusions were required for nonmalignant diseases. The duration of the transfusion-dependent period was influenced by the type of diagnosis, haematopoietic stem cell source and donor type. Gender differences between donor and recipient, as well as differences in ABO and conditioning regime did not influence either transfusion requirement or independence from transfusions. Conclusion. This analysis presents the need for transfusions of donor blood components in allogeneic HSCT recipients during 1 year. The results of the analysis can be used for planning the activities of transplantation centres and blood service institutions to provide transfusion support for HSCT recipients.
- 14 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32039
Microphotopheresis for the Treatment of Graft‐Versus‐Host Disease in Pediatric Patients
Introduction: Extracorporeal photopheresis (ECP) is an attractive treatment for graft‐versus‐host disease (GVHD) following allogeneic hematopoietic stem cell transplantation due to the lack of systemic immunosuppression. Modifications of ECP without leukapheresis are being actively studied in clinical practice around the world. A low‐volume method of extracorporeal photochemotherapy—micro‐ECP—has been developed at the Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology. We present the results of using micro‐ECP to treat acute and chronic GVHD. Patients and methods: We analyzed the treatment outcomes of 9 cases of acute GVHD and 15 cases of chronic GVHD using micro‐ECP for the period from April 2021 to March 2024. The cellular product was obtained by collecting 20–30 mL of whole blood followed by photochemical treatment. The processed autologous cell product was administered to the patient. Results: The overall response rate in patients diagnosed with acute GVHD was 44%, while the organ‐specific response rate was 56% for skin and 40% for gastrointestinal. The steroid‐sparing effect for acute GVHD was 89%. In the treatment of chronic GVHD, the overall response rate was 73.3%. The organ‐specific response rate was 71% for skin, 67% for gastrointestinal, 67% for lung, 100% for eyes, and 100% for liver chronic GVHD. The steroid‐sparing effect for chronic GVHD was 63%. Conclusion: In the treatment of acute and chronic GVHD, micro‐ECP has demonstrated promising efficacy. Although the method remains experimental, it is already apparent that micro‐ECP constitutes an attractive alternative to standard ECP when leukapheresis is not a viable option.
- 14 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32039
Microphotopheresis for the Treatment of Graft‐Versus‐Host Disease in Pediatric Patients
Introduction: Extracorporeal photopheresis (ECP) is an attractive treatment for graft‐versus‐host disease (GVHD) following allogeneic hematopoietic stem cell transplantation due to the lack of systemic immunosuppression. Modifications of ECP without leukapheresis are being actively studied in clinical practice around the world. A low‐volume method of extracorporeal photochemotherapy—micro‐ECP—has been developed at the Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology. We present the results of using micro‐ECP to treat acute and chronic GVHD. Patients and methods: We analyzed the treatment outcomes of 9 cases of acute GVHD and 15 cases of chronic GVHD using micro‐ECP for the period from April 2021 to March 2024. The cellular product was obtained by collecting 20–30 mL of whole blood followed by photochemical treatment. The processed autologous cell product was administered to the patient. Results: The overall response rate in patients diagnosed with acute GVHD was 44%, while the organ‐specific response rate was 56% for skin and 40% for gastrointestinal. The steroid‐sparing effect for acute GVHD was 89%. In the treatment of chronic GVHD, the overall response rate was 73.3%. The organ‐specific response rate was 71% for skin, 67% for gastrointestinal, 67% for lung, 100% for eyes, and 100% for liver chronic GVHD. The steroid‐sparing effect for chronic GVHD was 63%. Conclusion: In the treatment of acute and chronic GVHD, micro‐ECP has demonstrated promising efficacy. Although the method remains experimental, it is already apparent that micro‐ECP constitutes an attractive alternative to standard ECP when leukapheresis is not a viable option.
- Open Access
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 54-62
Transfusions of pathogen-reduced components of donor blood to recipients of allogeneic hematopoietic stem cell transplantation
Introduction. Pathogen reduction technologies (PRT) in donor blood components have become a new milestone in ensuring the safety of transfusions. However, it is widely acknowledged that the use of PRT can compromise the quality of blood components and potentially diminish the efficiency of transfusion.The purpose of this retrospective analysis is the presentation of the results of the use of pathogenic-reduced components of donor blood in comparison with standard transfusion practice in hematopoietic stem cell transplantation (HSCT) recipients.Materials and methods. An analysis was conducted of the results of transfusions to recipients of allogeneic HSCT performed in 2018–2022. We presented results of 1901 red blood cell transfusions (1848 of which were gamma-irradiated and 53 were pathogen-reduced), 8192 platelet concentrates transfusions (7654 of which were gamma-irradiated and 538 were pathogen-reduced) and donor plasma transfusions (freshly frozen plasma (FFP) – 1381, pathogen-reduced – 169).Results. The estimated laboratory efficiency of the transfusion of pathogen-reduced red blood cells was comparable to that of gamma-irradiated. Platelet concentrates subjected to pathogen reduction, as well as those prepared using an additional solution, demonstrated the lowest results of post-transfusion increase compared to gamma-irradiated platelet concentrates. Plasma processed using the pathogen reduction method resulted in a smaller increase in fibrinogen concentration. All other hemostasis indices were comparable to those of FFP.Conclusion. The clinical use of pathogen-reduced donor blood components is an effective transfusion practice, but further improvements in TRP are needed.
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 54-62
Open AccessTransfusions of pathogen-reduced components of donor blood to recipients of allogeneic hematopoietic stem cell transplantation
Introduction. Pathogen reduction technologies (PRT) in donor blood components have become a new milestone in ensuring the safety of transfusions. However, it is widely acknowledged that the use of PRT can compromise the quality of blood components and potentially diminish the efficiency of transfusion.The purpose of this retrospective analysis is the presentation of the results of the use of pathogenic-reduced components of donor blood in comparison with standard transfusion practice in hematopoietic stem cell transplantation (HSCT) recipients.Materials and methods. An analysis was conducted of the results of transfusions to recipients of allogeneic HSCT performed in 2018–2022. We presented results of 1901 red blood cell transfusions (1848 of which were gamma-irradiated and 53 were pathogen-reduced), 8192 platelet concentrates transfusions (7654 of which were gamma-irradiated and 538 were pathogen-reduced) and donor plasma transfusions (freshly frozen plasma (FFP) – 1381, pathogen-reduced – 169).Results. The estimated laboratory efficiency of the transfusion of pathogen-reduced red blood cells was comparable to that of gamma-irradiated. Platelet concentrates subjected to pathogen reduction, as well as those prepared using an additional solution, demonstrated the lowest results of post-transfusion increase compared to gamma-irradiated platelet concentrates. Plasma processed using the pathogen reduction method resulted in a smaller increase in fibrinogen concentration. All other hemostasis indices were comparable to those of FFP.Conclusion. The clinical use of pathogen-reduced donor blood components is an effective transfusion practice, but further improvements in TRP are needed.
- Open Access
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 51-61
Pathogen-reduced red blood cell suspension in pediatric transfusion practice
Introduction. Pathogen reduction technologies in donor blood products have provided a preventive approach against a variety of hemotransmissive infections as well as prevention of donor leukocyte complications. However, while pathogen reduction in plasma and platelet concentrates is currently widespread, methods for reducing pathogens in red blood cell (RBC)-containing products are still being studied.Aim: to analyze the transfusion results of a pathogen-reduced RBC suspension in patients with various oncological and hematological diseases as well as defects of the immune system in order to prevent transfusion transmission of cytomegalovirus infection.Patients and methods. The results of transfusion therapy of a pathogen-reduced RBC suspension for the prevention of transfusion transmission of CMV infection in 27 patients who underwent transfusions during a long follow-up period are presented.Results. A total of 27 patients received 167 transfusions of pathogen-reduced RBC suspension. Transfusion efficacy, assessed by hemoglobin increase, was dependent on the transfusion volume per body weight, but was independent of the storage time of the RBC suspension over the measured interval. The transfusions were effective and tolerated without complications.Conclusion. The clinical use of pathogen-reduced RBC suspension is safe and provides sufficient clinical and laboratory efficacy.
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 51-61
Open AccessPathogen-reduced red blood cell suspension in pediatric transfusion practice
Introduction. Pathogen reduction technologies in donor blood products have provided a preventive approach against a variety of hemotransmissive infections as well as prevention of donor leukocyte complications. However, while pathogen reduction in plasma and platelet concentrates is currently widespread, methods for reducing pathogens in red blood cell (RBC)-containing products are still being studied.Aim: to analyze the transfusion results of a pathogen-reduced RBC suspension in patients with various oncological and hematological diseases as well as defects of the immune system in order to prevent transfusion transmission of cytomegalovirus infection.Patients and methods. The results of transfusion therapy of a pathogen-reduced RBC suspension for the prevention of transfusion transmission of CMV infection in 27 patients who underwent transfusions during a long follow-up period are presented.Results. A total of 27 patients received 167 transfusions of pathogen-reduced RBC suspension. Transfusion efficacy, assessed by hemoglobin increase, was dependent on the transfusion volume per body weight, but was independent of the storage time of the RBC suspension over the measured interval. The transfusions were effective and tolerated without complications.Conclusion. The clinical use of pathogen-reduced RBC suspension is safe and provides sufficient clinical and laboratory efficacy.
- Open Access
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 98-103
Using a low-volume method of extracorporeal photochemotherapy. Description of clinical cases
Extracorporeal photopheresis (ECP) has proven effective in the treatment of several diseases, including acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. In its standard version, ECP requires leukapheresis to obtain a fraction of mononuclear cells. The possibility of using leukapheresis is limited by the requirements for vascular access and the somatic status of the patient.In the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia was developed a new ECP method that does not require leukapheresis. This paper presents a description of two clinical cases of severe refractory GVHD treated by micro-ECP.
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 98-103
Open AccessUsing a low-volume method of extracorporeal photochemotherapy. Description of clinical cases
Extracorporeal photopheresis (ECP) has proven effective in the treatment of several diseases, including acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. In its standard version, ECP requires leukapheresis to obtain a fraction of mononuclear cells. The possibility of using leukapheresis is limited by the requirements for vascular access and the somatic status of the patient.In the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia was developed a new ECP method that does not require leukapheresis. This paper presents a description of two clinical cases of severe refractory GVHD treated by micro-ECP.
- Open Access
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 484-498-498
Clinical application of a low-volume extracorporeal photochemotherapy for the treatment of graft-versus-host disease
Introduction. Extracorporeal photopheresis (ECP) is an attractive method of treating graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation due to the lack of systemic immunosuppression. However, the clinical use of ECP is often limited by the need for leukapheresis. There are modifications of ECP without the use of leukapheresis, in particular low-volume ECP.Aim: to analyze the use of lv-ECP for the treatment of patients with acute and chronic GvHD.Patients and methods. The results of treatment of 9 cases of acute GVHD and 15 cases of chronic GVHD using the lv-ECP from April 2021 to March 2024 are presented. The cellular product was obtained by effusion of 15-30 ml of whole blood followed by photochemical treatment. The processed autologous cell product was administered to the patient.Results. The overall response in patients with acute GVHD was 44%, organ-specific response for skin lesions was 56 %, and for gastrointestinal lesions, 40%. In the treatment of chronic GvHD, the overall response was 73.3 %; the effectiveness of therapy for skin lesions was 71 %; for gastrointestinal lesions 67 %; for lung damage 67 %; for eye damage 100 %, for liver damage 100 %.Conclusion. lv-ECP has shown promising efficacy results in the treatment of acute and chronic GvHD. lv-ECP is an attractive alternative to standard ECP when leukapheresis is not possible.
- 28 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 484-498-498
Open AccessClinical application of a low-volume extracorporeal photochemotherapy for the treatment of graft-versus-host disease
Introduction. Extracorporeal photopheresis (ECP) is an attractive method of treating graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation due to the lack of systemic immunosuppression. However, the clinical use of ECP is often limited by the need for leukapheresis. There are modifications of ECP without the use of leukapheresis, in particular low-volume ECP.Aim: to analyze the use of lv-ECP for the treatment of patients with acute and chronic GvHD.Patients and methods. The results of treatment of 9 cases of acute GVHD and 15 cases of chronic GVHD using the lv-ECP from April 2021 to March 2024 are presented. The cellular product was obtained by effusion of 15-30 ml of whole blood followed by photochemical treatment. The processed autologous cell product was administered to the patient.Results. The overall response in patients with acute GVHD was 44%, organ-specific response for skin lesions was 56 %, and for gastrointestinal lesions, 40%. In the treatment of chronic GvHD, the overall response was 73.3 %; the effectiveness of therapy for skin lesions was 71 %; for gastrointestinal lesions 67 %; for lung damage 67 %; for eye damage 100 %, for liver damage 100 %.Conclusion. lv-ECP has shown promising efficacy results in the treatment of acute and chronic GvHD. lv-ECP is an attractive alternative to standard ECP when leukapheresis is not possible.
- Open Access
- 8 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 182-191
Extracorporeal photopheresis for the treatment of graft-versus-host disease after hematopoietic stem cell transplantation
Graft-versus-host disease (GVHD) is one of the main complications of allogeneic hematopoietic stem cell transplantation. A large number of patients do not respond to corticosteroid therapy and require alternative treatment options. Extracorporeal photopheresis (ECP) is an empirically developed cell therapy that has proven effective in the treatment of both acute and chronic GVHD. Because ECP is safe to use and has few serious side effects, its application in the management of GVHD is very attractive. The purpose of this paper is to present a literature review on the use of ECP for the treatment of GVHD.
- 8 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 182-191
Open AccessExtracorporeal photopheresis for the treatment of graft-versus-host disease after hematopoietic stem cell transplantation
Graft-versus-host disease (GVHD) is one of the main complications of allogeneic hematopoietic stem cell transplantation. A large number of patients do not respond to corticosteroid therapy and require alternative treatment options. Extracorporeal photopheresis (ECP) is an empirically developed cell therapy that has proven effective in the treatment of both acute and chronic GVHD. Because ECP is safe to use and has few serious side effects, its application in the management of GVHD is very attractive. The purpose of this paper is to present a literature review on the use of ECP for the treatment of GVHD.
- 17 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30800
Extracorporeal photopheresis: Is one ounce of blood enough? Case reports
Extracorporeal photopheresis (ECP) has proven effective in the treatment of several diseases, including acute and chronic graft‐versus‐host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. In its standard version, ECP requires leukapheresis to obtain a fraction of mononuclear cells. The possibility of using leukapheresis is limited by the requirements for vascular access and the somatic status of the patient. We have developed a new ECP method that does not require leukapheresis. This paper presents a description of two clinical cases of severe refractory GVHD treated by micro‐ECP.
- 17 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30800
Extracorporeal photopheresis: Is one ounce of blood enough? Case reports
Extracorporeal photopheresis (ECP) has proven effective in the treatment of several diseases, including acute and chronic graft‐versus‐host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. In its standard version, ECP requires leukapheresis to obtain a fraction of mononuclear cells. The possibility of using leukapheresis is limited by the requirements for vascular access and the somatic status of the patient. We have developed a new ECP method that does not require leukapheresis. This paper presents a description of two clinical cases of severe refractory GVHD treated by micro‐ECP.
- Open Access
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 159-165
Extracorporeal photopheresis: how, why and for whom?
Extracorporeal photopheresis is a method of cell therapy that was developed and introduced into clinical practice of various specialties over 30 years ago but its mechanism of action, clinical application and the possibility of further modification are still on the minds of scientists around the world. Here we provide a review of the existing literature on the major critical aspects of the extracorporeal photopheresis technology as well as information on possible ways of modifying the method, the current understanding of its mechanism of effectiveness, the use in various diseases and pathological conditions and a list of possible side effects.
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 159-165
Open AccessExtracorporeal photopheresis: how, why and for whom?
Extracorporeal photopheresis is a method of cell therapy that was developed and introduced into clinical practice of various specialties over 30 years ago but its mechanism of action, clinical application and the possibility of further modification are still on the minds of scientists around the world. Here we provide a review of the existing literature on the major critical aspects of the extracorporeal photopheresis technology as well as information on possible ways of modifying the method, the current understanding of its mechanism of effectiveness, the use in various diseases and pathological conditions and a list of possible side effects.